Thrombin Generation in Chronic Liver Diseases-A Pilot Study

Overview

Journal Healthcare (Basel)

Specialty Health Services

Date 2021 Jun 2

PMID 34066706

Citations 2

Authors

Liliana Vecerzan

Ariela Olteanu

Ionela Maniu

Adrian Boicean

Calin Remus Cipaian

Horatiu Dura

Sorin Radu Fleaca

Romeo Gabriel Mihaila

Affiliations

Soon will be listed here.

Abstract

The knowledge about coagulation disorders in patients with chronic liver disease changed in the last decade. The aim of this study was to analyze the parameters of thrombin generation in patients with chronic liver disease, as they are the most appropriate biomarkers to explore coagulation. (1) Background: The knowledge about coagulation disorders in patients with chronic liver disease changed in the last decade. The study of thrombin generation in patients with chronic liver disease provides a much more accurate assessment of the coagulation cascade; (2) Methods: This study is a prospective observational pilot study on hospitalized patients with chronic liver diseases that analyzed thrombin generation performed from their platelet-poor plasma versus that of control subjects. We analyzed a group of 59 patients with chronic liver disease and 62 control subjects; (3) Results: Thrombin generation was lower in hepatitis and cirrhosis patients compared to controls and decreases as the disease progressed. Lag time was higher in ethanolic etiology compared to the control group. Peak thrombin and endogenous thrombin potential were shorter in all etiologies when compared to the control group. The velocity index was significantly lower in HCV hepatopathies, ethanolic, and mixed etiology when compared with normal individuals; (4) Conclusions: Given the variability of thrombin generation in patients with chronic liver disease, its assay could serve to identify patients with high thrombotic and hemorrhagic risk and establish personalized conduct toward them.

Citing Articles

Correlation Between Thrombin Generation and Hepatic Fibrosis in Chronic Liver Diseases.

Vecerzan L, Maniu I, Cioca G Cureus. 2024; 16(10):e71376.

PMID: 39539923 PMC: 11558027. DOI: 10.7759/cureus.71376.

Proteomics identifies complement protein signatures in patients with alcohol-associated hepatitis.

Taiwo M, Huang E, Pathak V, Bellar A, Welch N, Dasarathy J JCI Insight. 2024; 9(9).

PMID: 38573776 PMC: 11141929. DOI: 10.1172/jci.insight.174127.

References

Askgaard G, Tolstrup J, Kjaer M, Leon D . Number of hospital contacts with alcohol problems predicts later risk of alcoholic liver cirrhosis. Scand J Public Health. 2018; 47(4):417-419. DOI: 10.1177/1403494818763436. View

Lisman T, Porte R . Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases. Res Pract Thromb Haemost. 2018; 1(2):150-161. PMC: 6058283. DOI: 10.1002/rth2.12028. View

Intagliata N, Argo C, Stine J, Lisman T, Caldwell S, Violi F . Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference. Thromb Haemost. 2018; 118(8):1491-1506. PMC: 6202935. DOI: 10.1055/s-0038-1666861. View

Sinegre T, Duron C, Lecompte T, Pereira B, Massoulier S, Lamblin G . Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis. J Thromb Haemost. 2018; 16(6):1132-1140. DOI: 10.1111/jth.14011. View

Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M . Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005; 41(3):553-8. DOI: 10.1002/hep.20569. View

Wan J, Roberts L, Hendrix W, Konings J, Ow T, Rabinowich L . Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay. J Thromb Haemost. 2020; 18(4):834-843. PMC: 7186949. DOI: 10.1111/jth.14751. View

Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus J, Webber L . Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018; 69(3):718-735. DOI: 10.1016/j.jhep.2018.05.011. View

Bos S, van den Boom B, Kamphuisen P, Adelmeijer J, Blokzijl H, Schreuder T . Haemostatic Profiles are Similar across All Aetiologies of Cirrhosis. Thromb Haemost. 2019; 119(2):246-253. DOI: 10.1055/s-0038-1676954. View

Tripodi A, Primignani M, Chantarangkul V, Clerici M, DellEra A, Fabris F . Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology. 2006; 44(2):440-5. DOI: 10.1002/hep.21266. View

10.

Kalambokis G, Oikonomou A, Baltayiannis G, Christou L, Kolaitis N, Tsianos E . Thrombin generation measured as thrombin-antithrombin complexes predicts clinical outcomes in patients with cirrhosis. Hepatol Res. 2015; 46(3):E36-44. DOI: 10.1111/hepr.12520. View

11.

Chandler W, Dawson K, Ruegger M, Teruya M, Liebl P, Monsour H . Patients with cirrhosis show a relative increase in thrombin generation that is correlated with lower antithrombin levels. Blood Coagul Fibrinolysis. 2014; . DOI: 10.1097/MBC.0000000000000231. View

12.

Kremers R, Kleinegris M, Ninivaggi M, de Laat B, Ten Cate H, Koek G . Decreased prothrombin conversion and reduced thrombin inactivation explain rebalanced thrombin generation in liver cirrhosis. PLoS One. 2017; 12(5):e0177020. PMC: 5417641. DOI: 10.1371/journal.pone.0177020. View

13.

Lebreton A, Sinegre T, Lecompte T, Talon L, Abergel A, Lisman T . Thrombin Generation and Cirrhosis: State of the Art and Perspectives. Semin Thromb Hemost. 2020; 46(6):693-703. DOI: 10.1055/s-0040-1715102. View

14.

Saja M, Abdo A, Sanai F, Shaikh S, Abdel Gader A . The coagulopathy of liver disease: does vitamin K help?. Blood Coagul Fibrinolysis. 2012; 24(1):10-7. DOI: 10.1097/MBC.0b013e32835975ed. View

15.

Gatt A, Riddell A, Calvaruso V, Tuddenham E, Makris M, Burroughs A . Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost. 2010; 8(9):1994-2000. DOI: 10.1111/j.1538-7836.2010.03937.x. View

16.

Li B, Zhang C, Zhan Y . Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. Can J Gastroenterol Hepatol. 2018; 2018:2784537. PMC: 6051295. DOI: 10.1155/2018/2784537. View

17.

Chaireti R, Rajani R, Bergquist A, Melin T, Friis-Liby I, Kapraali M . Increased thrombin generation in splanchnic vein thrombosis is related to the presence of liver cirrhosis and not to the thrombotic event. Thromb Res. 2014; 134(2):455-61. DOI: 10.1016/j.thromres.2014.05.012. View

18.

Zermatten M, Fraga M, Calderara D, Aliotta A, Moradpour D, Alberio L . Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis. JHEP Rep. 2020; 2(4):100120. PMC: 7369360. DOI: 10.1016/j.jhepr.2020.100120. View

19.

Bitto N, Liguori E, La Mura V . Coagulation, Microenvironment and Liver Fibrosis. Cells. 2018; 7(8). PMC: 6115868. DOI: 10.3390/cells7080085. View

20.

Kujovich J . Coagulopathy in liver disease: a balancing act. Hematology Am Soc Hematol Educ Program. 2015; 2015:243-9. DOI: 10.1182/asheducation-2015.1.243. View